Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 13/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2605187 | 0.95 | SLC6A9 (0.62) | SLC6A9KMT2AATMMEN1ALDH1A1 | |
| SCHEMBL2605226 | 0.95 | SLC6A9 (0.67) | SLC6A9KMT2AATMMEN1ALDH1A1 | |
| SCHEMBL2605218 | 0.89 | SLC6A9 (0.71) | SLC6A9KMT2AATMMEN1ALDH1A1 | |
| SCHEMBL2605265 | 0.88 | SLC6A9 (0.69) | SLC6A9KMT2AATMMEN1ALDH1A1 | |
| SCHEMBL2605316 | 0.87 | SLC6A9 (0.76) | SLC6A9KMT2AATMRAB9A | |
| SCHEMBL2123074 | 0.87 | SLC6A9 (0.76) | SLC6A9KMT2AATMRAB9A | |
| SCHEMBL2605366 | 0.85 | SLC6A9 (0.73) | SLC6A9KMT2AATMMEN1ALDH1A1 | |
| SCHEMBL2605228 | 0.85 | SLC6A9 (0.73) | SLC6A9KMT2AATMMEN1ALDH1A1 | |
| SCHEMBL2605219 | 0.84 | SLC6A9 (0.71) | SLC6A9KMT2AATMMEN1ALDH1A1 | |
| SCHEMBL2605212 | 0.84 | SLC6A9 (0.71) | SLC6A9KMT2AATMMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094995-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2012-04-19 | — | — | US | disclosed |
| US-20120094995-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2012-04-19 | — | — | US | disclosed |
| WO-2010087762-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094995-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF | SLC1A2, B4GALT1, SLC6A1 | SLC6A9 50/4885KMT2A 969/4885ATM 4420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.